Company: IMCR
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001671927-25-000014
Chunk: 61

Company: Immunocore Holdings plc
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 8
Chunk 61
---
 30,Six Months Ended June 30,2025202420252024United States$64,087 $55,606 $120,694 $105,632 Europe33,042 15,404 65,846 34,356 International835 4,337 5,305 5,701 Revenue from sale of therapies, net$97,964 $75,347 $191,845 $145,689 Revenue from sale of therapies, net for the three and six months ended June 30, 2025 included $5.2 million and $12.6 million, respectively (2024: $5.0 million and $7.2 million, respectively), of partnered revenue pursuant to the Company's separate agreements with Medison Pharma Ltd. ("Medison") and Er-Kim Pharmaceuticals Bulgaria EOOD ("Er-Kim"). Revenue from these agreements is allocated between the Company's European and international markets.Accounts receivable from contracts with customersAccounts receivable as of June 30, 2025 and December 31, 2024 were $69.8 million and $63.0 million, respectively. An allowance for lifetime expected credit losses on accounts receivable is measured using historical credit loss experience, conditions at the end of each reporting period, and reasonable and supportable forecasts that affect collectability. Expected credit losses as of June 30, 2025 and December 31, 2024 were immaterial.Accruals for rebates, chargebacks and returnsCurrent and non-current accruals for rebates, chargebacks and returns as of June 30, 2025 were as follows (in thousands): RebatesChargebacksReturnsTotalAs of December 31, 2024$108,521 $2,038 $365 $110,924 Provisions related to sales in the period78,009 20,001 7,247 105,257 Adjustments related to sales in prior periods(5,983)— — (5,983)Credits and payments made(34,372)(19,578)(6,780)(60,730)As of June 30, 2025$146,175 $2,461 $832 $149,468     

9

Table of Contents

Included in the above are non-current accruals for rebates, chargebacks and returns of $83.4 million and $0 million as of June 30